Browse P4HA2

Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum lumen.
Domain PF13640 2OG-Fe(II) oxygenase superfamily
PF08336 Prolyl 4-Hydroxylase alpha-subunit
Function

Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.

> Gene Ontology
 
Biological Process GO:0018126 protein hydroxylation
GO:0018208 peptidyl-proline modification
GO:0019511 peptidyl-proline hydroxylation
Molecular Function GO:0004656 procollagen-proline 4-dioxygenase activity
GO:0005506 iron ion binding
GO:0009055 electron carrier activity
GO:0016701 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen
GO:0016702 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016706 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
GO:0019798 procollagen-proline dioxygenase activity
GO:0019842 vitamin binding
GO:0031406 carboxylic acid binding
GO:0031418 L-ascorbic acid binding
GO:0031543 peptidyl-proline dioxygenase activity
GO:0031545 peptidyl-proline 4-dioxygenase activity
GO:0043168 anion binding
GO:0051213 dioxygenase activity
Cellular Component GO:0005788 endoplasmic reticulum lumen
> KEGG and Reactome Pathway
 
KEGG hsa00330 Arginine and proline metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-1474290: Collagen formation
R-HSA-1474244: Extracellular matrix organization
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between P4HA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of P4HA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of P4HA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9330.0476
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8940.683
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9540.53
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1440.772
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0860.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4420.871
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0390.946
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4540.774
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6160.717
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9750.583
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7440.515
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2430.0492
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of P4HA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of P4HA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of P4HA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by P4HA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of P4HA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of P4HA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between P4HA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolP4HA2
Nameprolyl 4-hydroxylase, alpha polypeptide II
Aliases C-P4Halpha(II); 4-PH alpha 2; collagen prolyl 4-hydroxylase alpha(II); procollagen-proline, 2-oxoglutarate 4 ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting P4HA2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting P4HA2.
ID Name Drug Type Targets #Targets
DB00139Succinic acidSmall MoleculeALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4H ......26
DB00172L-ProlineSmall MoleculeEPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, ......21